Loading...
•
Mar 31, 2022
Heron Therapeutics Q1 2022 Earnings Report
Heron Therapeutics reported a net loss for Q1 2022 and saw increased demand for ZYNRELEF.
Key Takeaways
Heron Therapeutics reported a net loss of $63.9 million, or $0.63 per share, for the three months ended March 31, 2022. ZYNRELEF unit demand increased 68% compared to the prior quarter, and Oncology Care Franchise net revenue increased by 13% over the prior quarter.
ZYNRELEF unit demand increased 68% in the first quarter compared to the prior quarter.
CMS approved a 3-year transitional pass-through status for ZYNRELEF beginning April 1, 2022.
Oncology Care Franchise net revenue was $22.4 million in Q1 2022, a 13% increase over the prior quarter.
Full-year 2022 net revenue for the Oncology Care Franchise is expected to be $89 million to $93 million.
Heron Therapeutics
Heron Therapeutics
Heron Therapeutics Revenue by Segment
Revenue by Segment
CINVANTI Revenue
CapyFin.comSUSTOL Revenue
CapyFin.comZYNRELEF Revenue
CapyFin.com Forward Guidance
Heron Therapeutics expects continued strong growth in the current quarter with the receipt of pass-through status from CMS for HOPD and anticipates net product sales of $22 million to $23 million in the second quarter of 2022 and full year 2022 net product sales of $89 million to $93 million for the oncology care franchise.
Revenue & Expenses
Visualization of income flow from segment revenue to net income